Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | POLG | P54098 | 1/20 | 0.34 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17617642 | 0.94 | FGFR1 (0.41) | TP53MAPTTLR9TLR7HSP90AA1 | |
| SCHEMBL18665248 | 0.91 | POLB (0.38) | TP53MAPTTLR9TLR7HSP90AA1 | |
| SCHEMBL17617641 | 0.88 | TLR9 (0.35) | TP53MAPTTLR9TLR7HSP90AA1 | |
| SCHEMBL7867774 | 0.81 | HSP90AA1 (0.39) | MAPTHSP90AA1HSP90AB1NR3C1 | |
| SCHEMBL17617648 | 0.74 | TLR9 (0.31) | TLR9TLR7 | |
| SCHEMBL9583524 | 0.73 | CDK2 (0.41) | — | |
| SCHEMBL7161328 | 0.72 | FGFR1 (0.52) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL7867908 | 0.72 | PTGS2 (0.42) | — | |
| SCHEMBL9583064 | 0.70 | CDK5 (0.38) | TP53MAPT | |
| SCHEMBL21317387 | 0.66 | CDK2 (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | TP53 102/4885MAPT 4876/4885TLR9 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.